123 related articles for article (PubMed ID: 36484305)
21. [Therapeutic effects of medroxyprogesterone acetate in recurrent or advanced breast cancer].
Yoshida M; Murai H; Miura S
Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):516-23. PubMed ID: 3159345
[TBL] [Abstract][Full Text] [Related]
22. High-dose medroxyprogesterone acetate (MPA) treatment in advanced breast cancer. A review.
Ganzina F
Tumori; 1979 Oct; 65(5):563-85. PubMed ID: 390798
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant therapy for operable breast cancer with medroxyprogesterone acetate alone in postmenopausal patients or in combination with CMF in premenopausal patients.
Pannuti F; Martoni A; Cilenti G; Camaggi CM; Fruet F
Eur J Cancer Clin Oncol; 1988 Mar; 24(3):423-9. PubMed ID: 2968262
[TBL] [Abstract][Full Text] [Related]
24. High-dose medroxyprogesterone acetate in advanced breast cancer. Clinical and pharmacokinetic study with a combined oral and intramuscular regimen.
Becher R; Miller AA; Höffken K; Gerhold U; Hirche H; Schmidt CG
Cancer; 1989 May; 63(10):1938-43. PubMed ID: 2522811
[TBL] [Abstract][Full Text] [Related]
25. High progesterone receptor concentration in a variant of the ZR-75-1 human breast cancer cell line adapted to growth in oestrogen free conditions.
van den Berg HW; Martin J; Lynch M
Br J Cancer; 1990 Apr; 61(4):504-7. PubMed ID: 2139575
[TBL] [Abstract][Full Text] [Related]
26. Response to medroxyprogesterone acetate (NSC-26386) as secondary hormone therapy for metastatic breast cancer in postmenopausal women.
Klaassen DJ; Rapp EF; Hirte WE
Cancer Treat Rep; 1976 Mar; 60(3):251-3. PubMed ID: 1260780
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic effect of tamoxifen related to estrogen receptor level.
Rose C; Thorpe SM; Løber J; Daenfeldt JL; Palshof T; Mouridsen HT
Recent Results Cancer Res; 1980; 71():134-41. PubMed ID: 6988911
[TBL] [Abstract][Full Text] [Related]
28. Chemotherapy with or without high-dose medroxyprogesterone acetate in oestrogen-receptor-negative advanced breast cancer. Norwegian Breast Cancer Group.
Gundersen S; Kvinnsland S; Klepp O; Lund E; Hannisdal E; Høst H
Eur J Cancer; 1992; 28(2-3):390-4. PubMed ID: 1534248
[TBL] [Abstract][Full Text] [Related]
29. High dose medroxyprogesterone acetate (MPA) treatment in metastatic carcinoma of the breast: a dose-response evaluation.
Cuna GR; Calciati A; Strada MR; Bumma C; Campio L
Tumori; 1978 Apr; 64(2):143-9. PubMed ID: 354147
[TBL] [Abstract][Full Text] [Related]
30. The effects of sequential treatment with ethynyloestradiol and medroxyprogesterone acetate on oestrogen and progestogen receptors in breast cancer.
Ghilchik M; Shaikh NA; Beranek PA; Reed MJ; Braunsberg H
J Steroid Biochem; 1989; 34(1-6):403-5. PubMed ID: 2533948
[TBL] [Abstract][Full Text] [Related]
31. Depomedroxyprogesterone acetate therapy for hot flashes in survivors of breast cancer: no unfavorable impact on recurrence and survival.
Ertz-Archambault NM; Rogoff LB; Kosiorek HE; Ernst BJ; Anderson KS; Pockaj BA; Gray RJ; Northfelt DW
Support Care Cancer; 2020 May; 28(5):2139-2143. PubMed ID: 31402403
[TBL] [Abstract][Full Text] [Related]
32. A randomized comparison of megestrol acetate (MA) and medroxyprogesterone acetate (MPA) in patients with advanced breast cancer.
Willemse PH; van der Ploeg E; Sleijfer DT; Tjabbes T; van Veelen H
Eur J Cancer; 1990 Mar; 26(3):337-43. PubMed ID: 2141491
[TBL] [Abstract][Full Text] [Related]
33. [A case of disseminated breast cancer successfully treated with medroxyprogesterone acetate].
Tsumura I; Okamura Y; Takatsuka Y; Kobayakawa K; Kawahara T
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1509-12. PubMed ID: 2143889
[TBL] [Abstract][Full Text] [Related]
34. Response to third-line endocrine treatment for advanced breast cancer.
Iveson TJ; Ahern J; Smith IE
Eur J Cancer; 1993; 29A(4):572-4. PubMed ID: 8435212
[TBL] [Abstract][Full Text] [Related]
35. Medroxyprogesterone acetate at very high doses in postmenopausal advanced breast cancer patients.
Pannuti F; Longhi A; Martoni A; Piana E; Baroni M
Chemioterapia; 1987 Dec; 6(6):396-8. PubMed ID: 2963702
[TBL] [Abstract][Full Text] [Related]
36. Maintenance treatment with medroxyprogesterone acetate in patients with advanced breast cancer responding to chemotherapy: results of a randomized trial. Essen Breast Cancer Study Group.
Kloke O; Klaassen U; Oberhoff C; Hartwich G; Szanto J; Wolf E; Heckmann M; Huhn R; Stephan L; Schnepper U; Donsbach GM; Bechtel C; Rudolph R; Berke A; Borquez D; Hawig I; Hirche H; Schindler AE; Seeber S; Becher R
Breast Cancer Res Treat; 1999 May; 55(1):51-9. PubMed ID: 10472779
[TBL] [Abstract][Full Text] [Related]
37. Influence of tamoxifen-medroxyprogesterone sequential therapy on estrogen and progesterone receptor contents of breast cancer.
Noguchi S; Yamamoto H; Inaji H; Imaoka S; Koyama H
Jpn J Cancer Res; 1989 Mar; 80(3):244-8. PubMed ID: 2524460
[TBL] [Abstract][Full Text] [Related]
38. A phase II study of medroxyprogesterone acetate in patients with hormone receptor negative metastatic breast cancer: translational breast cancer research consortium trial 007.
Miller KD; Althouse SK; Nabell L; Rugo H; Carey L; Kimmick G; Jones DR; Merino MJ; Steeg PS
Breast Cancer Res Treat; 2014 Nov; 148(1):99-106. PubMed ID: 25257727
[TBL] [Abstract][Full Text] [Related]
39. Oral high-dose medroxyprogesterone acetate treatment for recurrent breast cancer.
Iino Y; Takeo T; Sugamata N; Aoyagi H; Takai Y; Takei H; Ando T; Koibuchi Y; Yokoe T; Ohwada S
Anticancer Res; 1995; 15(3):1061-4. PubMed ID: 7645926
[TBL] [Abstract][Full Text] [Related]
40. High-dose oral medroxyprogesterone acetate in heavily pretreated patients with metastatic breast cancer.
Goss PE; Ashley S; Powles TJ; Coombes RC
Cancer Treat Rep; 1986 Jun; 70(6):777-9. PubMed ID: 2942246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
